Rapport Therapeutics Plunges 14.43% on Earnings Outlook

On March 28, 2025, Rapport Therapeutics' stock experienced a significant drop of 14.43% in pre-market trading.

Rapport Therapeutics' earnings are projected to improve from a loss of $3.65 per share to a loss of $3.37 per share in the coming year. This anticipated improvement in financial performance could be a key factor influencing investor sentiment and stock price movements.

The FDA's issuance of an approvable letter for Nyxoah's Genio® system has also drawn attention to the biotechnology sector, potentially impacting investor perceptions of companies like Rapport Therapeutics.